Palmitoylated analogs of neuropeptide PrRP31 previously showed anorexigenic effects and central c-Fos activation after peripheral administration, as well as increased central insulin and leptin signaling, suggesting great potential for the treatment of not only obesity but also neurodegenerative disorders [9,34,35]. Here, FOS is linked to obesity due to melanocortin 4 receptor deficiency.